{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T12:48:35Z","timestamp":1751374115596,"version":"3.37.3"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,1,11]],"date-time":"2017-01-11T00:00:00Z","timestamp":1484092800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100007489","name":"Bausch and Lomb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007489","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1007\/s40268-016-0164-6","type":"journal-article","created":{"date-parts":[[2017,1,11]],"date-time":"2017-01-11T02:05:05Z","timestamp":1484100305000},"page":"167-175","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Besifloxacin Ophthalmic Suspension 0.6% Compared with Gatifloxacin Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis in Neonates"],"prefix":"10.1007","volume":"17","author":[{"given":"Christine M.","family":"Sanfilippo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine M.","family":"Allaire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heleen H.","family":"DeCory","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,1,11]]},"reference":[{"key":"164_CR1","unstructured":"American Optometric Association. Care of the patient with conjunctivitis. 2002. Available at: https:\/\/www.aoa.org\/documents\/CPG-11.pdf . Accessed 22 June 2016."},{"key":"164_CR2","first-page":"1000119","volume":"2","author":"SK Palafox","year":"2011","unstructured":"Palafox SK, Jasper S, Tauber AD, Foster SC. Ophthalmia neonatorum. J Clin Exp Ophthalmol. 2011;2:1000119.","journal-title":"J Clin Exp Ophthalmol."},{"issue":"11","key":"164_CR3","first-page":"1187","volume":"59","author":"A Matejcek","year":"2013","unstructured":"Matejcek A, Goldman RD. Treatment and prevention of ophthalmia neonatorum. Can Fam Physician. 2013;59(11):1187\u201390.","journal-title":"Can Fam Physician."},{"issue":"8","key":"164_CR4","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3928\/00904481-20120727-05","volume":"41","author":"SL Block","year":"2012","unstructured":"Block SL. Etiologic and therapeutic pitfalls of\u00a0newborn\u00a0conjunctivitis. Pediatr Ann. 2012;41(8):310\u20133.","journal-title":"Pediatr Ann."},{"issue":"4","key":"164_CR5","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S0008-4182(02)80114-4","volume":"37","author":"WB Jackson","year":"2002","unstructured":"Jackson WB, Low DE, Dattani D, Whitsitt PF, Leeder RG, MacDougall R. Treatment of acute bacterial conjunctivitis: 1% fusidic acid viscous drops vs. 0.3% tobramycin drops. Can J Ophthalmol. 2002;37(4):228\u201337.","journal-title":"Can J Ophthalmol."},{"issue":"1","key":"164_CR6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1553-2712.2007.tb00359.x","volume":"14","author":"PB Patel","year":"2007","unstructured":"Patel PB, Diaz MC, Bennett JE, Attia MW. Clinical features of\u00a0bacterial conjunctivitis\u00a0in children. Acad Emerg Med. 2007;14(1):1\u20135.","journal-title":"Acad Emerg Med."},{"key":"164_CR7","unstructured":"American Academy of Ophthalmology. Conjunctivitis summary benchmarks for preferred practice pattern\u00ae guidelines. 2015. Available at: https:\/\/prodc.aao.org\/summary-benchmark-detail\/conjunctivitis-summary-benchmark--october-2012 . Accessed 19 July 2016."},{"key":"164_CR8","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s40135-015-0080-x","volume":"3","author":"S Andalibi","year":"2015","unstructured":"Andalibi S, Haidara M, Bor N, Levin M. An update on neonatal and pediatric conjunctivitis. Curr Ophthalmol Rep. 2015;3:158\u201369.","journal-title":"Curr Ophthalmol Rep."},{"issue":"6","key":"164_CR9","doi-asserted-by":"crossref","first-page":"747","DOI":"10.2165\/00003495-200161060-00004","volume":"61","author":"A Smith","year":"2001","unstructured":"Smith A, Pennefather PM, Kaye SB, Hart CA. Fluoroquinolones:\u00a0place\u00a0in ocular therapy. Drugs. 2001;61(6):747\u201361.","journal-title":"Drugs"},{"key":"164_CR10","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/00055735-200408000-00007","volume":"15","author":"FS Mah","year":"2004","unstructured":"Mah FS. Fourth-generation fluoroquinolones: new topical agents in the war on ocular bacterial infections. Curr Opin Ophthalmol. 2004;15:316\u201320.","journal-title":"Curr Opin Ophthalmol."},{"issue":"Suppl 1","key":"164_CR11","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1016\/j.survophthal.2005.05.004","volume":"50","author":"LH Silver","year":"2005","unstructured":"Silver LH, Woodside AM, Montgomery DB. Clinical safety of moxifloxacin ophthalmic solution 0.5% (VIGAMOX) in pediatric and nonpediatric patients with bacterial conjunctivitis. Surv Ophthalmol. 2005;50(Suppl 1):S55\u201363.","journal-title":"Surv Ophthalmol."},{"issue":"4","key":"164_CR12","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1136\/bjo.2006.103556","volume":"91","author":"I Cochereau","year":"2007","unstructured":"Cochereau I, Meddeb-Ouertani A, Khairallah M, et al. 3-day treatment with azithromycin 1.5% eye drops versus 7-day treatment with tobramycin 0.3% for purulent bacterial conjunctivitis: multicentre, randomised and controlled trial in adults and children. Br J Ophthalmol. 2007;91(4):465\u20139.","journal-title":"Br J Ophthalmol."},{"issue":"6","key":"164_CR13","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1136\/bjophthalmol-2013-303888","volume":"98","author":"D Bremond-Gignac","year":"2014","unstructured":"Bremond-Gignac D, Nezzar H, Bianchi PE, et al. Efficacy and safety of azithromycin 1.5% eye drops in paediatric population with purulent\u00a0bacterial conjunctivitis. Br J Ophthalmol. 2014;98(6):739\u201345.","journal-title":"Br J Ophthalmol."},{"key":"164_CR14","unstructured":"Bremond-Gignac\u00a0D, Messaoud R, Lazreg S, Speeg-Schatz C, Renault D, Chiambaretta F. A 3-day regimen with azithromycin 1.5% eyedrops for the treatment of purulent bacterial conjunctivitis in children: efficacy on clinical signs and impact on the burden of illness. Clin Ophthalmol. 2015;9:725\u201332."},{"issue":"13","key":"164_CR15","first-page":"1465","volume":"44","author":"RD Gross","year":"2003","unstructured":"Gross RD, Silas P, Oshman S, et al. A comparison of the safety and efficacy of moxifloxacin and ciprofloxacin in the treatment of presumed bacterial conjunctivitis in neonatal patients. Invest Ophthalmol Vis Sci. 2003;44(13):1465.","journal-title":"Invest Ophthalmol Vis Sci."},{"issue":"8","key":"164_CR16","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1128\/AAC.00418-09","volume":"53","author":"W Haas","year":"2009","unstructured":"Haas W, Pillar CM, Zurenko GE, Lee JC, Brunner LS, Morris TW. Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. Antimicrob Agents Chemother. 2009;53(8):3552\u201360.","journal-title":"Antimicrob Agents Chemother."},{"key":"164_CR17","unstructured":"Haas W, Gearinger LS, Usner DW, DeCory HH, Morris TW. Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: etiology of bacterial conjunctivitis and antibacterial susceptibility profile. Clin Ophthalmol. 2011;5:1369\u201379."},{"issue":"4","key":"164_CR18","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.ajo.2011.03.010","volume":"152","author":"W Haas","year":"2011","unstructured":"Haas W, Pillar CM, Torres M, Morris TW, Sahm DF. Monitoring antibiotic resistance in ocular microorganisms: results from the Antibiotic Resistance Monitoring in Ocular micRorganisms (ARMOR) 2009 surveillance study. Am J Ophthalmol. 2011;152(4):567\u201374.","journal-title":"Am J Ophthalmol."},{"key":"164_CR19","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1001\/jamaophthalmol.2015.3888","volume":"133","author":"PA Asbell","year":"2015","unstructured":"Asbell PA, Sanfilippo CM, Pillar CM, DeCory HH, Sahm DF, Morris TW. Antibiotic resistance among ocular pathogens in the United States: five-year results from the Antibiotic Resistance Monitoring in Ocular Microorganisms (ARMOR) surveillance study. JAMA Ophthalmol. 2015;133:1445\u201354.","journal-title":"JAMA Ophthalmol."},{"key":"164_CR20","unstructured":"Besivance [package insert]. Tampa: Bausch & Lomb; 2012."},{"issue":"2","key":"164_CR21","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2165\/11534380-000000000-00000","volume":"12","author":"TL Comstock","year":"2010","unstructured":"Comstock TL, Paterno MR, Usner DW, Pichichero ME. Efficacy and safety of\u00a0besifloxacin\u00a0ophthalmic suspension 0.6% in children and adolescents with bacterial conjunctivitis: a post hoc, subgroup analysis of three randomized, double-masked, parallel-group, multicenter clinical trials. Paediatr Drugs. 2010;12(2):105\u201312.","journal-title":"Paediatr Drugs."},{"key":"164_CR22","unstructured":"Zymar [package insert]. Irvine: Allergan, Inc.; 2015."},{"key":"164_CR23","unstructured":"Allergan. A study to evaluate the safety and efficacy of gatifloxacin for the treatment of bacterial conjunctivitis. ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). 2007 [cited 1 Sep 2016]. ClinicalTrials.gov identifier: NCT00464438. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00464438 ."},{"key":"164_CR24","first-page":"751","volume":"20","author":"GD Cagle","year":"1981","unstructured":"Cagle GD, Abshire RL. Quantitative ocular bacteriology: a method for the enumeration and identification of bacteria from the skin-lash margin and conjunctiva. Invest Ophthalmol Vis Sci. 1981;20:751\u20137.","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"164_CR25","unstructured":"Leibowitz HM. Antibacterial effectiveness of ciprofloxacin 0.3% ophthalmic solution in the treatment of bacterial conjunctivitis. Am J Ophthalmol. 1991;112(4 Suppl):29S\u201333S."},{"key":"164_CR26","unstructured":"Clinical and Laboratory Standards Institute. M07-A10. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard\u2013tenth edition. 2015. Available at: http:\/\/shop.clsi.org\/site\/Sample_pdf\/M07A10_sample.pdf . Accessed 19 July 2016."},{"key":"164_CR27","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1093\/jac\/dkq531","volume":"66","author":"W Haas","year":"2011","unstructured":"Haas W, Pillar CM, Hesje CK, Sanfilippo CM, Morris TW. In vitro time-kill experiments with besifloxacin, moxifloxacin and gatifloxacin in the absence and presence of benzalkonium chloride. J Antimicrob Chemother. 2011;66:840\u20134.","journal-title":"J Antimicrob Chemother."},{"issue":"5","key":"164_CR28","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1185\/03007990902837919","volume":"25","author":"ME Tepedino","year":"2009","unstructured":"Tepedino ME, Heller WH, Usner DW, et al. Phase III efficacy and safety study of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis. Curr Med Res Opin. 2009;25(5):1159\u2013639.","journal-title":"Curr Med Res Opin."},{"issue":"3","key":"164_CR29","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.clinthera.2009.03.010","volume":"31","author":"P Karpecki","year":"2009","unstructured":"Karpecki P, DePaolis M, Hunter JA. Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: a multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety study. Clin Ther. 2009;31(3):514\u201326.","journal-title":"Clin Ther."},{"issue":"9","key":"164_CR30","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.ophtha.2009.05.014","volume":"116","author":"MB McDonald","year":"2009","unstructured":"McDonald MB, Protzko EE, Brunner LS, et al. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis. Ophthalmology. 2009;116(9):1615\u201323.","journal-title":"Ophthalmology."},{"issue":"3","key":"164_CR31","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jaapos.2012.12.151","volume":"17","author":"M Amato","year":"2013","unstructured":"Amato M, Pershing S, Walvick M, Tanaka S. Trends in ophthalmic manifestations of methicillin-resistant Staphylococcus aureus (MRSA) in a northern California pediatric population. J AAPOS. 2013;17(3):243\u20137.","journal-title":"J AAPOS."},{"issue":"7","key":"164_CR32","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1097\/INF.0b013e31819988bf","volume":"28","author":"FC Lessa","year":"2009","unstructured":"Lessa FC, Edwards JR, Fridkin SK, Tenover FC, Horan TC, Gorwitz RJ. Trends in incidence of late-onset\u00a0methicillin-resistant Staphylococcus aureus\u00a0infection in neonatal intensive care units: data from the National Nosocomial Infections Surveillance System, 1995\u20132004. Pediatr Infect Dis J. 2009;28(7):577\u201381.","journal-title":"Pediatr Infect Dis J."},{"issue":"3","key":"164_CR33","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1089\/jop.2012.0081","volume":"29","author":"D Miller","year":"2013","unstructured":"Miller D, Chang JS, Flynn HW, Alfonso EC. Comparative in vitro susceptibility of\u00a0besifloxacin\u00a0and seven comparators against ciprofloxacin- and methicillin-susceptible\/nonsusceptible staphylococci. J Ocul Pharmacol Ther. 2013;29(3):339\u201344.","journal-title":"J Ocul Pharmacol Ther."}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-016-0164-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40268-016-0164-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-016-0164-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T03:54:44Z","timestamp":1498362884000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40268-016-0164-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,11]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["164"],"URL":"https:\/\/doi.org\/10.1007\/s40268-016-0164-6","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"type":"print","value":"1174-5886"},{"type":"electronic","value":"1179-6901"}],"subject":[],"published":{"date-parts":[[2017,1,11]]}}}